Drug interactions between Miradon and Vfend
| Results for the following 2 drugs: |
|---|
| Miradon (anisindione) |
| Vfend (voriconazole) |
Interactions between your selected drugs
anisindione ↔ voriconazole
Applies to:Miradon (anisindione) and Vfend (voriconazole)
MONITOR CLOSELY: Coadministration with voriconazole may significantly increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The mechanism is voriconazole inhibition of CYP450 2C9, 2C19 and 3A4, the isoenzymes responsible for the metabolic clearance of racemic warfarin. In healthy volunteers, coadministration of voriconazole (300 mg every 12 hours for 12 days) with warfarin (30 mg single dose on day 7) significantly increased maximum prothrombin time by approximately 2 times that observed with placebo. Prothrombin times were still increased by a mean value of 5.4 seconds 144 hours post warfarin dose following coadministration with voriconazole.
MANAGEMENT: Patients should be closely monitored during concomitant therapy with warfarin and voriconazole. The INR should be checked frequently and warfarin dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of voriconazole in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants, although clinical data are lacking.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
